|
| Press Releases |
|
 |
|
| Friday, May 29, 2020 |
|
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
| The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
| Monday, May 18, 2020 |
|
|
エーザイ、「新セルベール(R)整胃プレミアム＜錠＞」「新セルベール(R)整胃プレミアム＜細粒＞」新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、弱ってきた胃を粘液のベールで守り整える「セルベール」ブランドから、「新セルベール(R)整胃プレミアム＜錠＞」および「新セルベール(R)整胃プレミアム＜細粒＞」（いずれも第 2 類医薬品、以下 「新セルベール整胃プレミアム」）を本日、5 月 18 日（月）に全国の薬局・薬店、ドラッグストアにて新発売します。 more info >> |
|
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
| Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
| Thursday, May 14, 2020 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の開発品・製品に関する演題について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2020年5月29日-31日に開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（ASCO20 Virtual Scientific Program*）において、当社が創製したレンバチニブメシル酸塩（マルチキナーゼ阻害剤、製品名：「レンビマ(R)」、以下 レンバチニブ）、エリブリンメシル酸塩（ハリコンドリン系微小管ダイナミクス阻害剤、製品名：「ハラヴェン(R)」、以下 エリブリン）に関する最新知見を発表することをお知らせします。 more info >> |
|
| Tuesday, April 28, 2020 |
|
|
エーザイ、Institutional Investor誌の「The All-Japan Executive Team」において、「Most Honored Company」およびセクター第1位に選出 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、米国金融情報誌「Institutional Investor」がこのたび発表した「The All-Japan Executive Team」のBiotechnology & Pharmaceuticalsセクターにおいて、「Best CEOs」「Best CFOs」でそれぞれ第1位となり、「Most Honored Company」およびセクター総合第1位に選定されたことをお知らせします。 more info >> |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Thursday, April 2, 2020 |
|
|
エーザイと生化学工業、変形性関節症治療剤SI-613について中国における共同開発及び販売提携に関する契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と生化学工業株式会社（本社：東京都、代表取締役社長：水谷建、以下 生化学工業）は、このたび、生化学工業が創出した変形性関節症治療剤 SI-613（ジクロフェナク結合ヒアルロン酸）について、中国における共同開発及び販売提携に関する契約を締結しましたのでお知らせします。 more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
| Thursday, March 26, 2020 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
| Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY
Jan 22, 2025 21:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) 旗下子公司 Green Rain Solar Inc. 探討在紐約州希臘鎮出售太陽能農場開發權
Jan 22, 2025 21:00 HKT/SGT
|
|
|
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST
|
|
|
2nd Annual Operational Excellence & Business Transformation Summit: Operational Excellence in The Age of Digital Transformation, Building A Sustainable and Collaborative Future in Asia
Jan 22, 2025 16:15 HKT/SGT
|
|
|
Introducing the Sonim XP400: a 5g Smartphone Engineered for Demanding Days with Unmatched Durability, Now Available in EMEA and Australia
Jan 22, 2025 15:09 HKT/SGT
|
|
|
エーザイ、「世界で最も持続可能な100社」に9回目の選定
Jan 22, 2025 14:40: JST
|
|
|
三菱重工、西武鉄道から西武鉄道山口線向け新型車両3編成（12両）を受注
Jan 22, 2025 14:30: JST
|
|
|
ACN Newswire and Corinium Intelligence Present: CISO Perth 2025 - Uniting Western Australia's Top InfoSec Leaders
Jan 22, 2025 14:28 HKT/SGT
|
|
|
ASEAN Finance Innovation Summit 2025: Unlocking the Future of Finance
Jan 22, 2025 14:25 HKT/SGT
|
|
|
Second Hong Kong Shopping Festival gets underway with seminars and consultancy services
Jan 22, 2025 11:54 HKT/SGT
|
|
|
Migrant Workers Honored at Indian New Year Celebrations
Jan 22, 2025 11:40 HKT/SGT
|
|
|
The Now Corporation（OTC: NWPN）看到加利福尼亞州社區太陽能專案的機會
Jan 21, 2025 21:00 HKT/SGT
|
|
|
The Now Corporation (OTC: NWPN) Sees Opportunities for Community Solar Projects in California
Jan 21, 2025 21:00 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 21, 2025 18:29 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
